期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 21, 期 12, 页码 3980-3989出版社
WILEY
DOI: 10.1111/ajt.16766
关键词
clinical research; practice; infection and infectious agents; viral; infectious disease; vaccine
资金
- Ajmera Transplant Centre, Toronto
- Public Health Agency of Canada through the COVID-19 Immunity Task Force
- Public Health Agency of Canada through the Vaccine Surveillance Reference Group
Solid organ transplant recipients are at high risk of severe COVID-19. A study on the immunogenicity of mRNA-1273 vaccine in this population showed that a subset of patients developed neutralizing antibodies and CD4+ T cell responses, emphasizing the importance of vaccination in this patient population.
Solid organ transplant recipients are at high risk of severe disease from COVID-19. We assessed the immunogenicity of mRNA-1273 vaccine using a combination of antibody testing, surrogate neutralization assays, and T cell assays. Patients were immunized with two doses of vaccine and immunogenicity assessed after each dose using the above tests. CD4+ and CD8+ T cell responses were assessed in a subset using flow-cytometry. A total of 127 patients were enrolled of which 110 provided serum at all time points. A positive anti-RBD antibody was seen in 5.0% after one dose and 34.5% after two doses. Neutralizing antibody was present in 26.9%. Of note, 28.5% of patients with anti-RBD did not have neutralizing antibody. T cell responses in a sub-cohort of 48 patients showed a positive CD4+ T cell response in 47.9%. Of note, in this sub-cohort, 46.2% of patients with a negative anti-RBD, still had a positive CD4+ T cell response. The vaccine was safe and well-tolerated. In summary, immunogenicity of mRNA-1273 COVID-19 vaccine was modest, but a subset of patients still develop neutralizing antibody and CD4+T- cell responses. Importantly polyfunctional CD4+T cell responses were observed in a significant portion who were antibody negative, further highlighting the importance of vaccination in this patient population. IRB Statement: This study was approved by the University Health Network Research Ethics Board (CAPCR ID 20-6069).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据